Document is current
Any future updates will be listed below
-
Authors
Dündar, Nazlıhan Boyacı https://orcid.org/0000-0003-4264-9249
Sarphie, David https://orcid.org/0000-0003-4302-5454
Yüce, Kenan https://orcid.org/0009-0007-4297-5876
Gaygısız, Ümmügülsüm https://orcid.org/0000-0002-6472-9429
Kaskatı, O. Tolga https://orcid.org/0000-0001-8299-2397
Türkoğlu, Melda https://orcid.org/0000-0003-4043-7082
Bıkmaz, Gülbin Aygencel https://orcid.org/0000-0002-8856-5019
Karabıyık, Lale https://orcid.org/0000-0002-6009-8324
Çağlar, Kayhan https://orcid.org/0000-0001-7257-6453
Bozdayı, Gülendam https://orcid.org/0000-0002-6036-6819
Mian, Rubina https://orcid.org/0000-0001-5247-9875
Moss, Paul https://orcid.org/0000-0002-6895-1967
İlhan, Mustafa Necmi https://orcid.org/0000-0003-1367-6328
-
Funding
Funding for this research was provided by:
Innovate UK (Project No. 56969)
HORIZON EUROPE Framework Programme (INNO4COV-19 (Grant agreement No 101016203))
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 27 September 2023
First Online: 6 October 2023
Declarations
:
: The study was approved by the Clinical Research Ethics Committee of Gazi University and conducted in the Intensive Care Unit (ICU) of Gazi University Hospital in accordance with the principles of the Declaration of Helsinki, including obtaining informed consent.
: Not applicable.
: Authors Mian and Sarphie declare that they are directors and principal shareholders of Seroxo Ltd, a private company developing clinical applications of the LIT™ system. The other authors declare no competing interests.
